NCT06806202 Warm Versus Conventional 2% Lignocaine for IANB Efficacy
| NCT ID | NCT06806202 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Armed Forces Institute of Dentistry, Pakistan |
| Condition | Success of Inferior Alveolar Nerve Block |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-12-15 |
| Primary Completion | 2025-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 200 participants in total. It began in 2024-12-15 with a primary completion date of 2025-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study compares the anesthetic efficacy of warm versus conventional 2% lignocaine for inferior alveolar nerve block in mandibular molars, evaluating success rates and onset time.
Eligibility Criteria
Inclusion Criteria: * Permanent teeth with acutely inflamed pulp without swelling or draining sinus. * Patient who have carious mandibular molars. * Patients of either gender aged between 18-50 years old. * Systemically healthy patients. * Patients who agree to attend for recall appointments and provide a written consent Exclusion Criteria: * Patients on preoperative analgesics and antibiotics. * Teeth with calcified canals and previously treated teeth. * Pregnant and lactating mothers. * Patients who are immunocompromised, anxious and mentally handicapped. * Patients who are allergic to lignocaine. * Non-vital or necrosed teeth.
Contact & Investigator
Kanza Ali Zafar, BDS
PRINCIPAL INVESTIGATOR
AFID
Frequently Asked Questions
Who can join the NCT06806202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Success of Inferior Alveolar Nerve Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06806202 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06806202 currently recruiting?
Yes, NCT06806202 is actively recruiting participants. Contact the research team at mahaalimirza5@gmail.com for enrollment information.
Where is the NCT06806202 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT06806202 clinical trial?
NCT06806202 is sponsored by Armed Forces Institute of Dentistry, Pakistan. The principal investigator is Kanza Ali Zafar, BDS at AFID. The trial plans to enroll 200 participants.